• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Deep (Brain) Thoughts with Medtronic's Neuromodulation President

    Grab and Go: Examining the Thrombectomy Device Market

    Fine Print: A Discourse on Additive Manufacturing

    MPO's 2022 Medtech Industry Year in Review

    Micro Molding for Medtech Is Miniature Magic
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    The Producto Group Appoints Mark C. Rauenzahn as Chief Executive Officer

    Coloplast Launches New Catheter in the U.S.

    Josh Ghaim and Sachin Jain Join Cue Health Board of Directors

    NAMSA Relaunches Medtech Outsourcing Solution

    Rollomatic Inc. Welcomes Joe Kane as CEO
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Deep (Brain) Thoughts with Medtronic's Neuromodulation President

    Grab and Go: Examining the Thrombectomy Device Market

    Fine Print: A Discourse on Additive Manufacturing

    MPO's 2022 Medtech Industry Year in Review

    Micro Molding for Medtech Is Miniature Magic
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Reflections on 2022 and What’s Ahead for Medtech: MPO Sounding Board

    3 Ways to Prepare for ISO 13485/Part 820 Harmonization

    A New Home for Theranos' Elizabeth Holmes?

    Health Cost Drivers for Large Employers

    Braving Change: Facing Fears in the Midst of Major Transitions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    LEMO USA Inc.

    Forefront Medical Technology

    Halkey-Roberts Corporation

    Paragon Medical

    Arthur G. Russell Co. Inc., The
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How Artificial Intelligence Can Combat Key Issues Impacting Healthcare

    Why Advanced Sensors Are Crucial Within Medical Pumps

    How Artificial Intelligence Could Help Prevent 80% of Chronic Diseases

    4 Ways to Use Injection Molding in Medical Device Manufacturing

    Telemedicine and Connectivity to Drive Material Innovation in the Near Future
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    LEMO USA Inc.

    Forefront Medical Technology

    Halkey-Roberts Corporation

    Paragon Medical

    Arthur G. Russell Co. Inc., The
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    FDA's New Actions Concerning the Digital Health Pre-Cert Pilot Program

    The program aims to promote a more efficient framework for the review of safe and effective digital health innovation.

    Scott Gottlieb, M.D., Commissioner, U.S. Food and Drug Administration01.08.19
    Digital technologies create new opportunities to transform health care and empower patients to make better informed decisions about their health. Digital tools are rapidly evolving, and to keep pace with this promising innovation, the FDA must modernize its approach to regulation.
     
    That’s why I announced in the Digital Health Innovation Action Plan that the FDA would pilot a Digital Health Precertification (Pre-Cert) Program to make sure that patients continue to have access to new treatments that meet our gold standard for safety and effectiveness. Since that announcement, we’ve been advancing policies that reimagine our oversight of digital health tools to be more efficient and promote patient safety throughout the product lifecycle. We’ve seen the promise of innovation in products like artificial intelligence software that can help alert physicians to a potential stroke and smartwatches that can help identify atrial fibrillation. We’re announcing that, based on the Pre-Cert pilot, we’ve drafted a regulatory framework to test new approaches for the review of digital health device applications.
     
    Our goal in piloting the Pre-Cert Program was to support the development of new technologies that are frequently updated, as well as to learn from software developers about the unique nature of their products. We focused on ways to streamline our oversight of digital health products by reviewing and appraising the developer’s culture of quality and organizational excellence. Our aim has been to develop a Pre-Cert program that would allow developers who have been assessed by the FDA for meeting specific excellence principles—known as an “Excellence Appraisal”—to participate in a more tailored premarket submission process appropriate for their specific type of digital device.
     
    Our digital health team has been working with patients, providers, the nine diverse companies participating in the Pre-Cert pilot program and other stakeholders to build this framework. We’re issuing three documents that, together, launch us into the next phase of the agency’s vision of Pre-Cert. These components are a key step in advancing the Pre-Cert model. We look forward to obtaining public input as we implement these elements in the coming months.
     
    First, one of the most important components is explaining our regulatory framework for the Pre-Cert program. We believe the most efficient way to test this type of program is to do so within the FDA’s current regulatory authorities. We know many stakeholders have had questions about how this would work. We’re releasing our outline, titled Regulatory Framework for Conducting the Pilot Program within Current Authorities, to describe how the agency intends to use our De Novo pathway for novel technologies to implement the next phase of the Pre-Cert pilot.
     
    Our De Novo pathway is well-suited to meet the goals of our Pre-Cert program because it is a pathway for certain novel types of low- to moderate-risk devices to obtain marketing authorization. Currently, firms submitting products for review under the De Novo pathway must also meet applicable Quality System Regulation (QSR) requirements, which include demonstrating software design control and validation, and current good manufacturing practices. These requirements are meant to demonstrate and provide assurance to the FDA that a manufacturer makes products that are safe and effective and meet the De Novo statutory standard. In the Pre-Cert model, many of these QSR requirements would be satisfied by information the FDA collected through the Excellence Appraisal process, which is aimed at evaluating the quality and excellence of the software developer for Pre-Cert. By collecting this information early, the Excellence Appraisal could be leveraged to streamline a developer’s De Novo submission, reducing content the developer would need to submit to the agency under the De Novo pathway since the information would already have been demonstrated and documented during the Excellence Appraisal. This allows the FDA to tailor the premarket submission content to the unique considerations related to each particular digital health device and enables more efficient evaluation of low-risk digital health devices.
     
    Second, to further refine how this De Novo process would work for Pre-Cert, we need to test this type of implementation, which is why we also released our Pre-Cert Test Plan for 2019. This year, we intend to test our pilot program to assess how Pre-Cert can maintain our standards for assuring safe and effective products, while still achieving its aim of modernizing and streamlining our review of novel digital health products. We want to test how the Pre-Cert approach utilizing the streamlined De Novo pathway compares to our traditional submission pathway. To do so, we will review the sponsor’s traditional De Novo submission for its device and using that same submission information we will, in parallel, review the sponsor’s Excellence Appraisal information with the proposed streamlined submission content. The sponsor will incur no additional burden. Instead, the FDA will set up two parallel review processes, one using the Pre-Cert model and one using the traditional approach to the review of a De Novo application.
     
    As highlighted in the test plan, this approach will help the FDA show that the combined assurance resulting from the proposed Excellence Appraisal and streamlined premarket review submission will provide the same quality and type of information necessary for the FDA’s determination of whether a software developer’s products meet the statutory safety and effectiveness standard, as compared to the FDA’s approach in reviewing these devices under the traditional De Novo review process. The results and learning from this testing will provide input for refining our Pre-Cert program as well as confirm the validity of the concept envisioned in the Pre-Cert framework. At the conclusion of the testing and refinement, we expect to have confirmed that the evidence collected through the proposed Excellence Appraisal and streamlined De Novo submission meets the statutory requirements for granting marketing authorization.
     
    Third, we are releasing an update to our Working Model that incorporates the Regulatory Framework and Test Plan described above, which will help us understand how well Pre-Cert will work now, but also help us establish the components we envision for the future of Pre-Cert. The Pre-Cert model begins with appraising the excellence of the firm and reviewing related documentation, including elements corresponding to De Novo submission content and Quality System requirements and documenting that review. This Excellence Appraisal step is followed by a review of the streamlined Pre-Cert De Novo request submission described in the Regulatory Framework, which would include submission elements and a manufacturer’s plan to monitor and evaluate the real-world performance of the software. Proactive monitoring of real-world performance enhances an understanding of how the software continues to perform while in use while helping the developer and the FDA to quickly identify and address potential safety issues along with additional benefits to patients.
     
    As I recently noted in an update on our Medical Device Safety Action Plan, access to robust and timely data, including more extensive and informative post-market data and real-world evidence, helps the FDA identify, communicate and act on new or increased medical device safety concerns. Such data serves as the foundation of our commitment to improving our nation’s post-market medical device surveillance. It’s one of the core pillars of our safety action plan. By utilizing the power of real-world performance data on software, Pre-Cert will help the FDA and developers better evaluate the real-world benefits and risks of these tools, and more quickly identify and address any issues and communicate safety information to patients.
     
    The Working Model describes the proposed approach for implementing Pre-Cert under our current authority. It also outlines the agency’s broader vision for Pre-Cert. Since launching the pilot program, we have been transparent about how we are building the program and have frequently requested and reviewed public feedback. In this third draft of the Working Model, the public will see how we’ve incorporated into the model the extensive feedback received, and we look forward to additional engagement on this version and the other documents released.
     
    Together, the plans we’re launching demonstrate our ongoing commitment to building a Pre-Cert program that recognizes the unique and iterative characteristics of digital health products, as well as their significant potential to improve the lives of patients. Our new actions will promote the development of novel, beneficial technology while ensuring that patients have access to high quality, safe and effective digital health devices.
    Related Searches
    • medical
    • quality
    • it
    • test
    Related Knowledge Center
    • Digital Health
    • Software & IT
      Loading, Please Wait..

      Trending
      • The Future Of Biomedical Engineering Advancements
      • Cirtec Medical Corporation Acquires Precision Components Business From QMD
      • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
      • Coloplast Launches New Catheter In The U.S.
      • A New Approach To Post-Market Surveillance
      Breaking News
      • The Producto Group Appoints Mark C. Rauenzahn as Chief Executive Officer
      • Coloplast Launches New Catheter in the U.S.
      • Josh Ghaim and Sachin Jain Join Cue Health Board of Directors
      • NAMSA Relaunches Medtech Outsourcing Solution
      • Rollomatic Inc. Welcomes Joe Kane as CEO
      View Breaking News >
      CURRENT ISSUE

      November 2022

      • MPO's 2022 Year in Review
      • Fine Print: A Discourse on Additive Manufacturing
      • Grab and Go: Examining the Thrombectomy Device Market
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      BAPP Paper Reviews Common Adulteration Practices Which Go Undetected
      CRN Announces Promotions and Welcomes New Staff Member
      Quercetin Ingredient Linked to Improved COVID-19 Recovery: Study
      Coatings World

      Latest Breaking News From Coatings World

      PPG Achieves ISO 14001 Certification of Environmental Management System
      AmCoat’s Rhino Shield and Floor Shield Break Records in 2022
      Automotive Industry Leaders Form Cofinity-X JV
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      The Producto Group Appoints Mark C. Rauenzahn as Chief Executive Officer
      Coloplast Launches New Catheter in the U.S.
      Josh Ghaim and Sachin Jain Join Cue Health Board of Directors
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Jones Healthcare Group Installs BOBST NOVACUT 106 ER Flatbed Die-Cutter
      Pfizer Revenues Soar to Record-Breaking $100B in 2022
      iuvo BioScience Appoints Industry Exec to Lead Lab Biz
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Pacifica is our Packager of the Year
      La Roche-Posay Named the Fastest Growing Skincare Brand of 2022 by NielsenIQ
      Disney Collaborates with Nailtopia on Limited-Edition Nail Collection
      Happi

      Latest Breaking News From Happi

      Color Street Launches ‘Through the Cosmos’ Collection
      Curl Care Collection is New at Native
      Color Street Pledges $100K To Support Military & Veteran Appreciation
      Ink World

      Latest Breaking News From Ink World

      International Paper Reports Full-Year, 4Q 2022 Results
      UFlex Exhibits Sustainable Printing, Packaging Solutions at Plast India 2023
      Early-Bird Registration Opens for Print UV 2023
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      SABIC announces value chain partnerships
      Digital Embellishment Alliance launches new website community
      FLAG achieves record membership in 2022
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Superior Felt & Filtration Adds Domestic Injection Molding to its Medical Filtration Capabilities
      Ahlstrom Launches New Generation FluoroFree Technology
      Berry to Begin Production at India Healthcare Hub Early This Year
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Mobi-C Cervical Disc Replacement Procedures Top 200,000
      OPUM, Corflex Global Partner on Knee Assessment Technology
      ODT's Most-Read Stories This Week—Jan. 28
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Johan Hjertonsson Proposed as New Chairman of ASSA ABLOY
      Durak Highlights SilverPro Conductive Threads
      Arkema Partners with Research Institute to Open Lab in Mulhouse, France

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login